Abstract：
OBJECTIVE: Previous studies have been inconsistent concerning the association between the prognostic value of CD30 expression and extranodal natural killer/T-cell lymphoma (ENKTL).
METHODS: CD30 expression in 82 patients with newly diagnosed ENKTL (mean age, 50 years; 73.2% male) was assessed by immunohistochemistry on paraffin-embedded sections. The level of CD30 expression was categorized into negative (0%, no staining) and positive groups.
RESULTS: Sixty-seven cases exhibited positive CD30 expression, and the main between-group difference was the Chinese Southwest Oncology Group and Asia Lymphoma Study Group (CA) ENKTL stage and Eastern Cooperative Oncology Group (ECOG) performance status. The cutoff point for CD30 expression was 40% by restricted cubic splines analysis. The overall survival of patients with high expression (>40%) was statistically superior to negative (0%) and low-expression groups. A positive correlation was observed between CD30 and Epstein-Barr virus-encoded small RNA status (r = 0.305). Multivariable analysis suggested that positive CD30 expression (hazard ratio, 0.420 [95% CI, 0.193-0.914]; P = .029) and CA advanced stage (hazard ratio, 2.844 [95% CI, 1.371-5.896]; P = .005) were independent prognostic factors for ENKTL.
CONCLUSIONS: Positive CD30 expression was a favorable prognostic factor for ENKTL, and CD30 expression could restratify the survival of patients in clinical subgroups.
METHODS: CD30 expression in 82 patients with newly diagnosed ENKTL (mean age, 50 years; 73.2% male) was assessed by immunohistochemistry on paraffin-embedded sections. The level of CD30 expression was categorized into negative (0%, no staining) and positive groups.
RESULTS: Sixty-seven cases exhibited positive CD30 expression, and the main between-group difference was the Chinese Southwest Oncology Group and Asia Lymphoma Study Group (CA) ENKTL stage and Eastern Cooperative Oncology Group (ECOG) performance status. The cutoff point for CD30 expression was 40% by restricted cubic splines analysis. The overall survival of patients with high expression (>40%) was statistically superior to negative (0%) and low-expression groups. A positive correlation was observed between CD30 and Epstein-Barr virus-encoded small RNA status (r = 0.305). Multivariable analysis suggested that positive CD30 expression (hazard ratio, 0.420 [95% CI, 0.193-0.914]; P = .029) and CA advanced stage (hazard ratio, 2.844 [95% CI, 1.371-5.896]; P = .005) were independent prognostic factors for ENKTL.
CONCLUSIONS: Positive CD30 expression was a favorable prognostic factor for ENKTL, and CD30 expression could restratify the survival of patients in clinical subgroups.
摘要：
目的：关于CD30表达与结外自然杀伤/T细胞淋巴瘤（ENKTL）的预后价值之间的关系，以前的研究一直不一致。
方法：82例初诊ENKTL患者的CD30表达（平均年龄，50岁；73.2％的男性）通过石蜡包埋切片的免疫组织化学进行评估。CD30表达水平分为阴性（0%，无染色)和阳性组。
结果：67例CD30阳性表达，组间差异主要是中国西南肿瘤组和亚洲淋巴瘤研究组（CA）的ENKTL阶段和东部合作肿瘤组（ECOG）的表现状态。通过限制性三次样条分析,CD30表达的截止点为40%。高表达（>40％）患者的总生存率在统计学上优于阴性（0％）和低表达组。CD30与EB病毒编码的小RNA状态呈正相关(r=0.305)。多变量分析表明CD30表达阳性(风险比，0.420[95%CI，0.193-0.914]；P=0.029)和CA晚期(危险比，2.844[95%CI，1.371-5.896]；P=0.005）是ENKTL的独立预后因素。
结论：CD30阳性表达是ENKTL的有利预后因素，CD30的表达限制了临床亚组患者的生存。
方法：82例初诊ENKTL患者的CD30表达（平均年龄，50岁；73.2％的男性）通过石蜡包埋切片的免疫组织化学进行评估。CD30表达水平分为阴性（0%，无染色)和阳性组。
结果：67例CD30阳性表达，组间差异主要是中国西南肿瘤组和亚洲淋巴瘤研究组（CA）的ENKTL阶段和东部合作肿瘤组（ECOG）的表现状态。通过限制性三次样条分析,CD30表达的截止点为40%。高表达（>40％）患者的总生存率在统计学上优于阴性（0％）和低表达组。CD30与EB病毒编码的小RNA状态呈正相关(r=0.305)。多变量分析表明CD30表达阳性(风险比，0.420[95%CI，0.193-0.914]；P=0.029)和CA晚期(危险比，2.844[95%CI，1.371-5.896]；P=0.005）是ENKTL的独立预后因素。
结论：CD30阳性表达是ENKTL的有利预后因素，CD30的表达限制了临床亚组患者的生存。
